Replication factor C (RFC) is closely related to tumor progression and metastasis. However, the functional significance of RFC2 in hepatocellular carcinoma remains unclear. In order to solve this problem, the expression of RFC2 in liver cancer patients was analyzed through ONCOMINE, UALCAN, Human Protein Atlas. Survival analysis was conducted using Kaplan–Meier plotter and GEPIA. GO and KEGG enrichment analyses were carried out. The protein–protein interaction (PPI) network was performed through Metascape. Western blotting, cell counting kit-8 and transwell assay were used to detect the effect of RFC2 on cell proliferation and migration. The transcription and protein level of RFC2 in HCC were overexpressed, which was significantly related to the clinical individual cancer stage and pathological tumor grade of HCC patients. In addition, in patients with liver cancer, higher RFC2 expression was found to be significantly correlated with shorter OS and DFS. Furthermore, the function of RFC2 in liver cancer was DNA replication, and its main mechanism was the phase transition of the cell cycle. Biological experiments demonstrated that knockdown of RFC2 reduced the proliferation and migration of HCC cells. RFC2 might promote the development of liver cancer, which might be achieved by regulating cell cycle and DNA replication. It could be used as a novel biomarker for the prognosis of liver cancer.

中文翻译：

---

上调的 RFC2 预测肝细胞癌的不利进展

复制因子 C (RFC) 与肿瘤进展和转移密切相关。然而，RFC2 在肝细胞癌中的功能意义仍不清楚。为了解决这个问题，通过ONCOMINE、UALCAN、Human Protein Atlas对肝癌患者RFC2的表达情况进行了分析。使用 Kaplan-Meier 绘图仪和 GEPIA 进行生存分析。进行了 GO 和 KEGG 富集分析。蛋白质-蛋白质相互作用（PPI）网络是通过 Metascape 进行的。Western blotting、细胞计数kit-8和transwell实验用于检测RFC2对细胞增殖和迁移的影响。RFC2在HCC中的转录和蛋白水平过表达，与HCC患者的临床个体癌症分期和病理肿瘤分级显着相关。此外，在肝癌患者中，发现较高的 RFC2 表达与较短的 OS 和 DFS 显着相关。此外，RFC2在肝癌中的功能是DNA复制，其主要机制是细胞周期的相变。生物学实验表明，RFC2 的敲低减少了 HCC 细胞的增殖和迁移。RFC2 可能促进肝癌的发展，这可能是通过调节细胞周期和 DNA 复制来实现的。可作为肝癌预后的新型生物标志物。生物学实验表明，RFC2 的敲低减少了 HCC 细胞的增殖和迁移。RFC2 可能促进肝癌的发展，这可能是通过调节细胞周期和 DNA 复制来实现的。可作为肝癌预后的新型生物标志物。生物学实验表明，RFC2 的敲低减少了 HCC 细胞的增殖和迁移。RFC2 可能促进肝癌的发展，这可能是通过调节细胞周期和 DNA 复制来实现的。可作为肝癌预后的新型生物标志物。